Is there a generic version of momelotinib available in China?

Momelotinib is a JAK inhibitor targeting myeloproliferative diseases such as myelofibrosis and has significant clinical therapeutic value. However, as of 2025, molotinib has not yet been officially launched in China, which means that patients cannot directly purchase the drug in regular domestic pharmacies or medical institutions. For patients who need this medicine, obtaining the medicine mainly depends on purchasing it through formal overseas channels.

In overseas markets, the original version of molotinib is mainly the American version, and the price is relatively high. The latest data shows that the price of the US version of molotinib can reach more than 200,000 yuan, which is a considerable financial burden for most patients. The high price limits access to many patients, forcing them to look for more economical alternatives or generics.

Although molotinib is not yet available in China, some generic drugs have appeared in overseas markets, providing patients with more choices. For example, the generic version of midostaurin produced by Lucius Company has been approved by the Ministry of Health of Laos, and its ingredients are basically the same as the original drug. The specification of the drug is 100mg*30 tablets, and the price is about 2,000 yuan, which is significantly lower than the original drug. The emergence of this generic drug brings more affordable treatment options to patients, especially in situations of greater financial pressure, which is more attractive.

Generally speaking, there is no generic version of molotinib in China, and patients can only rely on regular overseas channels if they need medication. In view of the large price difference, patients should weigh the choice of original drugs or generic drugs based on their own circumstances. At the same time, it is recommended to use medication under the guidance of a professional doctor to ensure the safety and effectiveness of treatment. In the future, with the advancement of drug approval, molotinib is expected to enter the domestic market and bring good news to more patients.

Reference materials:https://en.wikipedia.org/wiki/Momelotinib